GNRH1 and breast carcinoma: Leuprorelin acetate (leuprorelin), an LH-RH agonist, is available as depot formulations for subcutaneous administration every 1 or 3 months for the treatment of hormone-responsive cancers, such as prostate cancer [19] and premenopausal breast cancer [20–23].